Dr. Ghassan Abou-Alfa on Possible Second-Line Treatments for HCC Patients

November 11, 2015
Ghassan Abou-Alfa, MD

Ghassan Abou-Alfa says serafnib is currently the only first-line treatment approved for HCC based on the SHARP trial, where the treatment showed improved survival in patients from 7.9 months to 10.7 months.

Ghassan Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, talks about first- and second-line treatments for hepatocellular carcinoma (HCC). He says sorafenib is currently the only first-line treatment approved for HCC based on the SHARP trial, where the treatment showed improved survival in patients from 7.9 months to 10.7 months.

Abou-Alfa says he finds it interesting that second-line therapies are already being investigated despite there not being many options for first-line treatments. He says nivolumab and pembrolizumab may have a place in the treatment of HCC.